Literature DB >> 28734891

CT-Defined Prosthesis-Patient Mismatch Downgrades Frequency and Severity, and Demonstrates No Association With Adverse Outcomes After Transcatheter Aortic Valve Replacement.

John Mooney1, Stephanie L Sellers1, Phillip Blanke1, Philippe Pibarot2, Rebecca T Hahn3, Danny Dvir4, Pamela S Douglas5, Neil J Weissman6, Susheel K Kodali3, Vinod H Thourani7, Hasan Jilaihawi8, Omar Khalique3, Craig R Smith3, Shaw Hua Kueh1, Mickael Ohana1, Romi Grover1, Christopher Naoum1, Aaron Crowley9, Wael A Jaber10, Maria C Alu3, Rupa Parvataneni9, Michael Mack11, John G Webb1, Martin B Leon3, Jonathon A Leipsic12.   

Abstract

OBJECTIVES: This study sought to determine if indexed effective orifice area (EOAi), using left ventricular outflow tract measured from computed tomography (EOAiCT), reclassified prosthesis-patient mismatch (PPM) compared with conventional echocardiogram-defined measurements (EOAiTTE).
BACKGROUND: PPM does not predict mortality following transcatheter aortic valve replacement (TAVR). However, it is unknown if the EOAiCT of the left ventricular outflow tract improves risk stratification.
METHODS: A total of 765 TAVR patients from the PARTNER II (Placement of Aortic Transcatheter Valves II) trial S3i cohort were evaluated. EOAi was calculated using the continuity equation, and the left ventricular outflow tract area was derived from baseline computed tomography. Traditional echocardiographic categories defined PPM: absent (>0.85 cm2/m2), moderate (≥0.65 and ≤0.85 cm2/m2), or severe (≤0.65 cm2/m2). Correlation of EOAiCT and EOAiTTE to 1-year outcomes was performed.
RESULTS: The incidence of PPM was 24% with EOACT compared with 45% with EOAiTTE. Only 6% of PPM was graded severe by EOAiCT compared with 9% by EOAiTTE. EOAiTTE, but not EOAiCT, defined PPM showed association with reduced left ventricular mass regression (p = 0.03 vs. p = 0.52). There was no association between PPM and death or rehospitalization at 1 year with either modality. EOACT was associated with minor stroke at 1 year (log-rank p = 0.04), and EOAiTTE with stroke/transient ischemic attack (log-rank p = 0.030). Furthermore, when subjects with mild or greater paravalvular regurgitation were excluded, the presence of PPM did not show association with any outcome.
CONCLUSIONS: EOAiCT downgrades frequency and severity of PPM in patients after TAVR, and was not associated with mortality 1 year after TAVR. EOAiTTE, but not EOAiCT, was associated with less left ventricular mass regression.
Copyright © 2017 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  CT; echocardiography; prosthesis–patient mismatch; transcatheter aortic valve replacement

Mesh:

Year:  2017        PMID: 28734891     DOI: 10.1016/j.jcin.2017.05.031

Source DB:  PubMed          Journal:  JACC Cardiovasc Interv        ISSN: 1936-8798            Impact factor:   11.195


  11 in total

Review 1.  Pros and cons of transcatheter aortic valve implantation (TAVI).

Authors:  Juan A Terré; Isaac George; Craig R Smith
Journal:  Ann Cardiothorac Surg       Date:  2017-09

2.  Low Incidence of Prosthesis-Patient Mismatch Following Extremely Small Transcatheter Aortic Valve Replacement with 20-mm Sapien 3.

Authors:  Kazue Okajima; Ikki Komatsu; Todd B Seto
Journal:  Int J Angiol       Date:  2021-08-25

Review 3.  Prosthesis-patient mismatch after transcatheter aortic valve implantation.

Authors:  Masaki Miyasaka
Journal:  Cardiovasc Interv Ther       Date:  2022-06-16

4.  Early and mid-term results of isolated aortic valve neocuspidization in patients with aortic stenosis.

Authors:  Yasunori Iida; Susumu Fujii; Sho Akiyama; Shigeharu Sawa
Journal:  Gen Thorac Cardiovasc Surg       Date:  2018-07-25

Review 5.  Multimodality cardiac imaging in the 21st century: evolution, advances and future opportunities for innovation.

Authors:  Melissa A Daubert; Tina Tailor; Olga James; Leslee J Shaw; Pamela S Douglas; Lynne Koweek
Journal:  Br J Radiol       Date:  2020-11-25       Impact factor: 3.039

6.  Transcatheter valve-in-valve implantation in degenerated aortic bioprostheses: are patients with small surgical bioprostheses at higher risk for unfavourable mid-term outcomes?

Authors:  Clarence Pingpoh; Holger Schroefel; Tanja Franz; Martin Czerny; Maximilian Kreibich; Martin Moser; Christoph Bode; Friedhelm Beyersdorf; Franz-Josef Neumann; Willibald Hochholzer; Matthias Siepe
Journal:  Ann Cardiothorac Surg       Date:  2020-11

7.  Incidence and predictors of prosthesis-patient mismatch after TAVI using SAPIEN 3 in Asian: differences between the newer and older balloon-expandable valve.

Authors:  Masaki Miyasaka; Norio Tada; Masataka Taguri; Shigeaki Kato; Yusuke Enta; Masaki Hata; Yusuke Watanabe; Toru Naganuma; Masahiro Yamawaki; Futoshi Yamanaka; Shinichi Shirai; Hiroshi Ueno; Kazuki Mizutani; Minoru Tabata; Kensuke Takagi; Masanori Yamamoto; Kentaro Hayashida
Journal:  Open Heart       Date:  2021-03

8.  Impact of Prosthesis-Patient Mismatch on 1-Year Outcomes after Transcatheter Aortic Valve Implantation: Meta-analysis of 71,106 Patients.

Authors:  Michel Pompeu Barros Oliveira Sá; Luiz Rafael Pereira Cavalcanti; Felipe Augusto Santos Sarargiotto; Álvaro Monteiro Perazzo; Sérgio da Costa Rayol; Roberto Gouveia Silva Diniz; Frederico Browne Correia Araújo Sá; Alexandre Motta Menezes; Ricardo Carvalho Lima
Journal:  Braz J Cardiovasc Surg       Date:  2019-06-01

9.  Patient-Prosthesis Mismatch in Contemporary Small-Size Mechanical Prostheses Does Not Impact Survival at 10 Years.

Authors:  Horea Feier; Mihaela Mocan; Andrei Grigorescu; Lucian Falnita; Marian Gaspar; Constantin-Tudor Luca
Journal:  J Cardiovasc Dev Dis       Date:  2022-01-31

Review 10.  Clinical and Technical Challenges of Prosthesis-Patient Mismatch After Transcatheter Aortic Valve Implantation.

Authors:  Pier Pasquale Leone; Fabio Fazzari; Francesco Cannata; Jorge Sanz-Sanchez; Antonio Mangieri; Lorenzo Monti; Ottavia Cozzi; Giulio Giuseppe Stefanini; Renato Bragato; Antonio Colombo; Bernhard Reimers; Damiano Regazzoli
Journal:  Front Cardiovasc Med       Date:  2021-06-04
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.